Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2016 | Pages:
157 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Chronic Heart Failure - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Chronic Heart Failure - Pipeline Review, H1 2016', provides an overview of the Chronic Heart Failure pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Heart Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Heart Failure and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Chronic Heart Failure - The report reviews pipeline therapeutics for Chronic Heart Failure by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Chronic Heart Failure therapeutics and enlists all their major and minor projects - The report assesses Chronic Heart Failure therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Chronic Heart Failure Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Chronic Heart Failure - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Chronic Heart Failure pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Content 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Chronic Heart Failure Overview 9 Therapeutics Development 10 Pipeline Products for Chronic Heart Failure - Overview 10 Pipeline Products for Chronic Heart Failure - Comparative Analysis 11 Chronic Heart Failure - Therapeutics under Development by Companies 12 Chronic Heart Failure - Therapeutics under Investigation by Universities/Institutes 13 Chronic Heart Failure - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Chronic Heart Failure - Products under Development by Companies 17 Chronic Heart Failure - Products under Investigation by Universities/Institutes 18 Chronic Heart Failure - Companies Involved in Therapeutics Development 19 Amgen Inc. 19 AnGes MG, Inc. 20 Bayer AG 21 Capricor Therapeutics, Inc. 22 Celyad SA 23 Juventas Therapeutics, Inc. 24 Laboratoires Pierre Fabre SA 25 Les Laboratoires Servier SAS 26 Mast Therapeutics, Inc. 27 Mesoblast Limited 28 Novartis AG 29 Pfizer Inc. 30 PhaseBio Pharmaceuticals, Inc. 31 Sanofi 32 Stemedica Cell Technologies, Inc. 33 Vichem Chemie Research Ltd. 34 Zensun (Shanghai) Sci & Tech Co., Ltd. 35 Chronic Heart Failure - Therapeutics Assessment 36 Assessment by Monotherapy Products 36 Assessment by Combination Products 37 Assessment by Target 38 Assessment by Mechanism of Action 40 Assessment by Route of Administration 42 Assessment by Molecule Type 44 Drug Profiles 46 (sacubitril + valsartan) - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 BAY-1067197 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 beperminogene perplasmid - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 C3BSCQR-1 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 cenderitide - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 CLR-325 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 F-373280 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 finerenone - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 furosemide - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 ivabradine hydrochloride - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 JVS-100 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 MPC-150IM - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 Neucardin - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 omecamtiv mecarbil MR - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 PB-1046 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 rivaroxaban - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 SAR-296968 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 serelaxin - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 sildenafil citrate - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Small Molecules for Chronic Heart Failure - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 Synthetic Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 vepoloxamer - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 vericiguat - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 Chronic Heart Failure - Recent Pipeline Updates 94 Chronic Heart Failure - Dormant Projects 145 Chronic Heart Failure - Discontinued Products 147 Chronic Heart Failure - Product Development Milestones 148 Featured News & Press Releases 148 Apr 04, 2016: Cytokinetics Announces Start of Phase 2 Clinical Trial of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure 148 Apr 04, 2016: Results Of Vepoloxamer Nonclinical Studies In Advanced Heart Failure Presented At American College Of Cardiology 65th Annual Scientific Sessions & Expo 148 Apr 02, 2016: New analyses show Novartis' Entresto reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless 149 Mar 22, 2016: CardioCell Expands Chronic Heart Failure Phase IIa Clinical Trial to MedStar Washington Hospital Center 150 Mar 18, 2016: Celyad notifies the European Medicines Agency of its intention to file a Marketing Authorization Application for C-Cure 151 Jan 20, 2016: Breakthrough drug for heart failure now available in the UK 151 Dec 23, 2015: Celyad to Address US Institutional Investors in January at J.P. Morgan Healthcare Conference 152 Dec 21, 2015: Celyad receives clearance from the US FDA on its CHART-2 Phase III IND 153 Dec 02, 2015: New heart failure therapy projected to increase life expectancy 153 Dec 01, 2015: CardioCell Plans Phase IIb Clinical Trial Using Its Stem Cells for Patients With Chronic Heart Failure 154 Appendix 156 Methodology 156 Coverage 156 Secondary Research 156 Primary Research 156 Expert Panel Validation 156 Contact Us 156 Disclaimer 157
List of Tables
Number of Products under Development for Chronic Heart Failure, H1 2016 10 Number of Products under Development for Chronic Heart Failure - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Number of Products under Investigation by Universities/Institutes, H1 2016 13 Comparative Analysis by Late Stage Development, H1 2016 14 Comparative Analysis by Clinical Stage Development, H1 2016 15 Comparative Analysis by Early Stage Development, H1 2016 16 Products under Development by Companies, H1 2016 17 Products under Investigation by Universities/Institutes, H1 2016 18 Chronic Heart Failure - Pipeline by Amgen Inc., H1 2016 19 Chronic Heart Failure - Pipeline by AnGes MG, Inc., H1 2016 20 Chronic Heart Failure - Pipeline by Bayer AG, H1 2016 21 Chronic Heart Failure - Pipeline by Capricor Therapeutics, Inc., H1 2016 22 Chronic Heart Failure - Pipeline by Celyad SA, H1 2016 23 Chronic Heart Failure - Pipeline by Juventas Therapeutics, Inc., H1 2016 24 Chronic Heart Failure - Pipeline by Laboratoires Pierre Fabre SA, H1 2016 25 Chronic Heart Failure - Pipeline by Les Laboratoires Servier SAS, H1 2016 26 Chronic Heart Failure - Pipeline by Mast Therapeutics, Inc., H1 2016 27 Chronic Heart Failure - Pipeline by Mesoblast Limited, H1 2016 28 Chronic Heart Failure - Pipeline by Novartis AG, H1 2016 29 Chronic Heart Failure - Pipeline by Pfizer Inc., H1 2016 30 Chronic Heart Failure - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2016 31 Chronic Heart Failure - Pipeline by Sanofi, H1 2016 32 Chronic Heart Failure - Pipeline by Stemedica Cell Technologies, Inc., H1 2016 33 Chronic Heart Failure - Pipeline by Vichem Chemie Research Ltd., H1 2016 34 Chronic Heart Failure - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2016 35 Assessment by Monotherapy Products, H1 2016 36 Assessment by Combination Products, H1 2016 37 Number of Products by Stage and Target, H1 2016 39 Number of Products by Stage and Mechanism of Action, H1 2016 41 Number of Products by Stage and Route of Administration, H1 2016 43 Number of Products by Stage and Molecule Type, H1 2016 45 Chronic Heart Failure Therapeutics - Recent Pipeline Updates, H1 2016 94 Chronic Heart Failure - Dormant Projects, H1 2016 145 Chronic Heart Failure - Dormant Projects (Contd..1), H1 2016 146 Chronic Heart Failure - Discontinued Products, H1 2016 147
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
